Patents Assigned to Proteostasis Therapeutics, Inc.
  • Proteasome activity enhancing compounds
    Patent number: 11746098
    Abstract: The present invention is directed to compounds that inhibit Usp14, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: September 5, 2023
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Matthew Cullen, Sheila Hauck, Megan Foley, Bradley Tait, Markus Haeberlein
  • Proteasome activity enhancing compounds
    Patent number: 11560385
    Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: January 24, 2023
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Matthew Cullen, Cecilia M. Bastos, Daniel Parks, Benito Munoz
  • Compounds, compositions, and methods for modulating CFTR
    Patent number: 11248010
    Abstract: The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: February 15, 2022
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Benito Munoz, Daniel Parks, Cecilia M. Bastos
  • Proteasome activity enhancing compounds
    Patent number: 11242361
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: February 8, 2022
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
  • Compounds, compositions, and methods for modulating CFTR
    Patent number: 11136313
    Abstract: The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: October 5, 2021
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Benito Munoz, Cecilia M. Bastos, Daniel Parks, David Kombo
  • Compounds, compositions, and methods for increasing CFTR activity
    Patent number: 11098035
    Abstract: The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: August 24, 2021
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • Compounds, compositions, and methods of increasing CFTR activity
    Patent number: 11083709
    Abstract: The present disclosure features compounds such as those having the Formulae (I) and (II), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound, such as a compound of Formula (I) or (II).
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: August 10, 2021
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Benito Munoz, Cecilia M. Bastos, John Miller
  • Compounds, compositions, and methods for increasing CFTR activity
    Patent number: 10899751
    Abstract: The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: January 26, 2021
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Daniel Parks, Cecilia M. Bastos, Matthew Cullen, Benito Munoz
  • Compounds, compositions, and methods for increasing CFTR activity
    Patent number: 10738040
    Abstract: The present disclosure features disclosed compounds which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: August 11, 2020
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
    Patent number: 10738011
    Abstract: The present disclosure is based, in part, on the discovery that disclosed compounds such as those having Formula (IVa), (Va), (IV), or (V) can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: August 11, 2020
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • Compounds, compositions, and methods for modulating CFTR
    Patent number: 10662207
    Abstract: The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: May 26, 2020
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Benito Munoz, Daniel Parks, Cecilia M. Bastos
  • Compounds, compositions, and methods for modulating CFTR
    Patent number: 10550106
    Abstract: The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: February 4, 2020
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Benito Munoz, Cecilia M. Bastos, Daniel Parks, David Kombo
  • Compounds, compositions, and methods of increasing CFTR activity
    Patent number: 10548878
    Abstract: The present disclosure features compounds such as those having the Formulae (I) and (II), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound, such as a compound of Formula (I) or (II).
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: February 4, 2020
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Benito Munoz, Cecilia M. Bastos, John Miller
  • Proteostasis regulators
    Patent number: 10532996
    Abstract: The present invention is directed to compounds having the Formulae (Ia-Ie), (II), (IIIa-IIId), (IVa-IVc), (Va-Vb), (VIa-VIe), (VII), (VIIIa-VIIIc), and (IX), pharmaceutically acceptable salts, prodrugs and solvates thereof, compositions of any of thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis comprising an effective amount of these compounds.
    Type: Grant
    Filed: January 10, 2017
    Date of Patent: January 14, 2020
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Megan Foley, Bradley Tait, Matthew Cullen
  • Compounds, compositions, and methods for increasing CFTR activity
    Patent number: 10392372
    Abstract: The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: August 27, 2019
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
    Patent number: 10392378
    Abstract: The present disclosure is based, in part, on the discovery that disclosed compounds such as those having Formula (IIIa), (III), or (IV) can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: August 27, 2019
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
    Patent number: 10344023
    Abstract: The present disclosure is based, in part, on the discovery that disclosed compounds can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: July 9, 2019
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • Compounds, compositions, and methods for increasing CFTR activity
    Patent number: 10174014
    Abstract: The present disclosure features disclosed compounds which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: January 8, 2019
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • METHODS OF TREATING PULMONARY DISEASES AND DISORDERS
    Publication number: 20180369209
    Abstract: The present disclosure features disclosed method of treating disorders such as COPD, bronchitis and/or asthma using disclosed compounds, optionally together with one or more additional active agents. Contemplated methods include administrating orally or by inhalation to a patient one or more disclosed compounds.
    Type: Application
    Filed: December 22, 2016
    Publication date: December 27, 2018
    Applicant: Proteostasis Therapeutics, Inc.
    Inventors: John Miller, Cecilia M. Bastos, Benito Munoz
  • Compounds, compositions, and methods for increasing CFTR activity
    Patent number: 10017503
    Abstract: The disclosure encompasses compounds having e.g., Formula (Ia) or (Ib), compositions thereof, and methods of modulating CFTR activity. The disclosure also encompasses methods of treating a condition associated with CFTR activity or condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a compound of Formula (I) or (Ib).
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: July 10, 2018
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait